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This paper reviews the current evidence regarding long-chained marine omega-3 polyunsaturated fatty acids (PUFAs) and
cardiovascular disease (CVD), their possible mechanisms of action, and results of clinical trials. Also, primary and secondary
prevention trials as studies on antiarrhythmic effects and meta-analyses are summarized. However, the individual bioavailability
of n-3 PUFAs along with the highly different study designs and estimations of FAs intake or supplementation dosages in patient
populations with different background intake of n-3 PUFAs might be some of the reasons for the inconsistent findings of the
studies evaluating the impact of n-3 PUFAs on CVD. The question of an optimum dose of n-3 PUFAs or whether there exists a
dose-response relation for n-3 PUFA supplementation is widely discussed. Moreover, the difficulties in interpreting meta-analyses
are clearly demonstrated by two recently published meta-analyses (Rizos et al. and Delgado Lista et al.), evaluating the efficacy
of n-3 PUFAs on CVD, including 12 common studies, but drawing opposite conclusions. We definitely need more large-scale,
randomized clinical trials of long duration, also reporting harmful effects of n-3 PUFAs.
1. Introduction
Unsaturated fatty acids (FAs), especially polyunsaturated
fatty acids (PUFAs), have since the 1970s been given a lot of
attention due to possible health promoting effects. During
the first decade of research, pilot studies on Greenland
Eskimos demonstrated that a diet rich in long-chained
marine PUFAs might reduce the incidence of ischemic heart
disease [1]. During the following decades, research has to a
large extent focused on the prevention and management of
cardiovascular disease (CVD).
During the same period of time, there has been a
large change in our understanding of the atherosclerotic
process. From being viewed as inanimate tubes, arteries
are now thought of as dynamic tissues, where intimal
inflammation plays a crucial role in the pathophysiologic
process of atherosclerotic development. A thin fibrous cap
is the only structure separating the blood compartment with
its coagulation factors from the prothrombotic material in
the lipid core. Enhanced inflammation might result in plaque
instability. Moreover, the endothelium plays a key role in
vascular homeostasis, and endothelial dysfunction seems to
be of major importance in the development of a vulnerable
plaque. The acute coronary syndrome (ACS) usually results
from the erosion or rupture of such a vulnerable atheroscle-
rotic plaque with subsequent coronary artery occlusion as
coagulation factors come into contact with tissue factor, the
major initiator of the extrinsic coagulation cascade [2].
The complex vascular biology preceding the ACS pro-
vides several possible therapeutic targets for PUFAs: reducing
atherosclerotic development, stabilizing vulnerable plaques,
and limiting the consequences of their disruption. Even
though a lot of research has been done trying to elucidate
the role of PUFAs in CVD prevention and management,
several issues are still under discussion. Clinical studies have
provided conflicting results, and the optimal intake of PUFAs
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is not firmly established. Concerns have been raised about
environmental contaminants accumulating in fish, especially
methylmercury, polychlorinated biphenyls, and dioxins, giv-
ing rise to possible deleterious effects [3] and counteracting
the beneficial cardioprotective effects of marine n-3 PUFAs
[4]. Especially mercury has been given a lot of attention
due to reports of a probable proatherosclerotic effect [5]. N-
3 PUFAs might also have a potential to increase oxidative
stress, resulting in lipid peroxides [6]. These issues might
be related to a dose optimum of n-3 PUFAs, as high doses
might exceed an optimum threshold level leading to lack of
beneficial effects due to lipid peroxidation or accumulation
of other toxic substances.
This paper reviews the current evidence regarding long-
chained marine omega-3 PUFAs and CVD, their possible
mechanisms of action, and results of clinical trials.
1.1. PUFAs—Chemistry and Origin. FAs are single-lipid
components comprised of a straight hydrocarbon chain
terminating with a carboxylic acid group (–COOH) at the
polar hydrophilic end and a nonpolar hydrophobic methyl
group (–CH3) at the other end. The various FAs are named
according to their number of carbon atoms and their number
and position of carbon-carbon double bonds. FAs with at
least two double bonds are designated as polyunsaturated.
For PUFAs, the position of the first double bond from the
methyl- (n/omega-) end of the molecule has given rise to
the terminology n-3 (omega-3) FAs, n-6 (omega-6) FAs,
and n-9 (omega-9) FAs [7]. According to the accepted
terminology, the number of carbon atoms in a PUFA
molecule is designated by the first figure, while the number
of double bonds is given by the second figure.
N-3 and n-6 PUFAs are not synthesized by the human
body, as they are essential FAs that need to be ingested [8].
While n-6 PUFAs and α-linolenic acid (18 : 3 n-3) are found
in vegetable foods, n-3 PUFAs with more than 20 carbon
atoms are made by phytoplankton and mainly ingested from
fatty fish and marine animals. The two most important
marine FAs with respect to human health are thought to be
eicosapentaenoic acid (EPA; 20 : 5 n-3) and docosahexaenoic
acid (DHA; 22 : 6 n-3). Even though these two FAs to a
small extent also can be derived from α-linolenic acid by
desaturation and elongation in the liver [8], the main body
content of EPA and DHA is dependent on the amount
ingested. For the present paper we will focus on these long-
chained marine n-3 PUFAs.
2. Mechanisms of Action of Long-Chained
Marine N-3 PUFAs
The observed health effects of n-3 PUFAs are mainly thought
to be mediated by two mechanisms: a change in the
properties of the cell membranes and the regulation of gene
transcription. As FAs are incorporated into cell membrane
phospholipids, the FA composition of this lipid bilayer is
reflected by the composition of FAs ingested. Increasing the
amounts of n-3 PUFAs in the cell membrane alters its bio-
chemical and physical properties with a subsequent change
of membrane fluidity, permeability, and electrophysiological
characteristics [9]. Changing membrane properties might
further affect the ability of membrane receptors to interact
with their ligands or intracellular signalling molecules as well
as modulate the effect of membrane bound enzymes [10].
There is also evidence for n-3 PUFAs themselves serving
as ligands for nuclear receptors affecting gene expression,
nuclear factor κB (NF-κB), and peroxisome proliferator-
activated receptor-γ (PPAR-γ) being two of the potential
targets [11–13].
Furthermore, 20-carbon PUFAs (arachidonic acid (AA)
and EPA) released from cell membrane phospholipids
by phospholipase A2 are substrates for the synthesis of
eicosanoids, a family of biochemical mediators consisting
of prostaglandins (PGs), thromboxanes (TXs), leukotrienes
(LTs), and hydroxy fatty acids. Eicosanoids possess impor-
tant vasoactive regulatory properties, such as regulation of
platelet aggregability, endothelial cell motility, cell growth,
and chemotaxis [8, 14, 15]. With the increasing incorpora-
tion of n-3 PUFAs into cell membranes, the production of
eicosanoids is shifted from the 4 series of LTs and the 2 series
of PGs and TXs generated from AA to the 5 series of LTs
and the 3 series of PGs and TXs derived from EPA, the latter
being eicosanoid products leading to a more vasodilatory
state, reduced inflammatory responses in the injured vessel
wall, and less potent platelet aggregation [8, 14, 15].
A combination of these mechanisms, summarized in
Table 1, seems to be responsible for the majority of the pro-
posed antiatherothrombogenic and antiarrhythmic effects of
n-3 PUFAs [8, 14, 16, 17] further outlined below.
2.1. Marine N-3 PUFAs and Anti-Atherothrombogenic Effects.
In the early 1990s, the extent of atherosclerotic lesions in
the coronary arteries and the aortas from Alaskan natives
were demonstrated to be significantly lower as compared
to non-natives in all age-groups [18]. This was one of
the first indications of a possible antiatherosclerotic effect
of n-3 PUFAs. In accordance with this finding, a dietary
related incorporation of EPA and DHA into advanced human
atherosclerotic plaques has been demonstrated [19, 20] along
with the development of a more stable plaque morphology,
less susceptible to rupture, after n-3 PUFA supplementation
[20]. The results from intervention studies on coronary
atherosclerosis progression and regression in humans have,
however, been highly diverging [21–23].
The potential effect on atherosclerosis was initially
thought to be related to the modulation of proatheroscle-
rotic risk factors. As compared to Danes, Greenland Inuits
had lower serum concentrations of total- and low-density
lipoprotein cholesterol, triglycerides, and very low-density
lipoprotein cholesterol but higher levels of high density
lipoprotein cholesterol [1, 24]. Since then, several studies
have confirmed that the increasing amounts of n-3 PUFAs
are associated with a more favourable profile of lipoproteins
[8]. The clear-cut triglyceride-lowering effect of marine n-3
PUFA especially is undisputed [8]. Several mechanisms may
contribute to the triglyceride-lowering effect by marine n-
3 PUFAs, such as reduced triglyceride synthesis and dimin-
ished chylomicron secretion from intestinal cells. Reduced
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Table 1: Mechanisms and biochemical effects of marine PUFA.
Anti-inflammatory effects
(i) Competition with AA for Cox/lipooxygenase sites
(ii) Increase of anti-inflammatory eicosanoids
(iii) Reduction of TNFα , IL-1, IL-6
(iv) Reduction of nuclear factor κB (NF- κB) activation
Vascular effects
(i) Increased vagal tone
(ii) Improved endothelial function
(iii) Increase of NO
(iv) Reduction of Hcy, VCAM-1, ELAM-1, and ICAM-1
(v) Reduction of ET-1
Antithrombotic effects
(i) Reduced platelet aggregation via reduction in TXA2
(ii) Increased bleeding time (high doses)
Triglyceride-lowering effect
Antiarrhythmic effects
(i) Increased membrane stabilization, reduced automaticity,
and increased refractory period
(ii) Increased EPA : AA ratio in plasma membrane of cardiac
myocytes
(iii) Reduced production of proarrhythmic eicosanoids
(iv) Reduced agonist affinity of beta-receptors → reduced
heart rate (HR), increased HR variability
(v) Inhibition of the L-type calcium current
(vi) Inhibition of fast voltage-dependent Na+ channels
triglyceride formation may partly be due to a reduced
pool of fatty acids substrate mediated through suppressed
hepatic fatty acid synthesis related to the effect by marine
n-3 PUFAs on hepatic gene expression downregulating de
novo lipogenesis, increased fatty acid beta-oxidation, and
reduced delivery of nonesterified fatty acids to the liver.
Besides, marine n-3 PUFAs are poor substrates for enzymes
responsible for triglyceride synthesis resulting in reduced and
impaired hepatic enzyme activity for triglyceride synthesis
and increased hepatic synthesis of phospholipids rather than
triglycerides, hereby limiting the secretion from the liver of
triglyceride-rich very low-density lipoprotein (VLDL) [8].
Furthermore, ingestion of n-3 PUFAs has been demon-
strated to have a blood pressure reducing effect [25], as well
as improving glucose metabolism/insulin resistance [26, 27].
The effect of n-3 PUFAs on insulin as a mediator of the
metabolic syndrome needs to be clarified, but there is some
support for a relationship between the content of n-3 PUFAs
in cell membranes and the action of insulin [8].
Lately, the role of inflammation and endothelial dys-
function in the pathophysiologic process of atherosclerosis
generation and disruption of the vulnerable atherosclerotic
plaque has been highlighted [28], opening a new area for
potential antiatherosclerotic effects of n-3 PUFAs. The first
demonstrated anti-inflammatory effects were related to a
shift in the production of eicosanoids by partial replacement
of AA by EPA in inflammatory cell membranes, as previously
described [8, 14, 15]. During recent years, other anti-
inflammatory effects of n-3 PUFAs, independent of the
altered eicosanoid production, have been demonstrated. This
comprises a reduced production of the proinflammatory
cytokines interleukin-1 (IL-1), IL-6, and tumour necro-
sis factor-α (TNF-α) from mononuclear cells as well as
decreased expression of E-selectin, intercellular adhesion
molecule-1 (ICAM-1), and vascular cell adhesion molecule-
1 (VCAM-1) on endothelial cells [8], the latter being the
molecules essential for the attachment of leucocytes to the
endothelium prior to their entrance into the intima. Cellular
adhesion molecules are markers of the functional state of
the endothelium, and their downregulation by n-3 PUFAs
have mainly been demonstrated in studies ex vivo. Moreover,
beneficial effects on the vasoregulatory secretagogues of the
endothelium, such as nitric oxide and prostacycline, have
been obtained by n-3 PUFAs [8].
The first studies from Bang and Dyerberg on Greenland
Eskimos also revealed an antithrombotic effect of high doses
of n-3 PUFAs associated with increased bleeding time [29,
30]. However, ingestion of less than 4 grams daily has not
been associated with increased risk of bleeding [8, 15, 31].
TXA2 is a potent prothrombotic agent, and it is therefore
likely that the observed antiplatelet effect of n-3 FAs, at
least to some extent, is mediated through a shift in the
eicosanoid production. Homocysteine (Hcy) may also exert
unfavourable effects on the antithrombotic properties of the
endothelium, and in a randomized trial previously presented
by our group we observed a reduction of Hcy after treatment
with a high dose of n-3 PUFAs as compared to corn oil
for 1 year following a myocardial infarction (MI) [32]. The
effect of these PUFAs on other haemostatic procoagulant
and fibrinolytic factors is, however, divergent [16, 33, 34],
and the final impact of n-3 PUFA supplementation on the
complex processes of vascular injury, thrombosis, and repair
still remains an unsettled issue.
2.2. Marine N-3 PUFAs and Antiarrhythmic Effects. The
reduction observed in cardiac death with increased intake
of n-3 PUFAs has largely been attributed to a potential
antiarrhythmic effect. Studies on cell cultures have revealed
that this might be related to a membrane stabilizing effect
in cardiac myocytes. Supplementation with n-3 PUFAs has
been found to enrich myocyte membranes with EPA and
DHA [35–37]. This induces a conformational change of the
cell membrane with effects on ion channels and membrane-
bound proteins resulting in a slight hyperpolarization of the
cell membrane, increasing the depolarizing stimuli necessary
to induce an action potential with subsequently reduced
automaticity. Furthermore, n-3 PUFAs affect the transition
of the voltage-gated sodium channel with a shift toward more
negative membrane voltages, promoting recovery from the
inactive state and thereby increasing the refractory period.
Both effects make the myocardium less excitable, especially in
ischemic tissue. In these cells, the negative potential required
to reactivate the Na channels might not be physiologically
obtainable due to the partial depolarization induced by the
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dysfunctional state of the Na/K-ATPases. Thus, n-3 PUFAs
might be important for opposing the effect of functional re-
entry substrates [9]. They are also capable of inhibiting the
voltage-dependent inward calcium current during phase 2
of an action potential. In cooperation with possible effects
on the Na/Ca exchanger and receptors in the sarcoplasmatic
reticulum, this might contribute to less intracellular Ca
fluctuations and reduced occurrence of after depolarizations
[9].
In addition to these direct effects on the generation and
duration of the action potential, other less direct mechanisms
of actions have been proposed. There is also evidence
for antiarrhythmic effects mediated through a reduced
production of proarrhythmic eicosanoids, reduced levels
of circulating catecholamines [38], and a reduced agonist
affinity of beta-receptors [17]. The latter observation might
be one of the mechanisms responsible for an improvement
in the cardiac sympathetic-vagal balance, revealed clinically
as a reduction in the mean heart rate (HR) [39] as
well as an increase in HR variability [40]. Both of these
parameters have been demonstrated to be related to the risk
of malignant arrhythmias and sudden cardiac death (SCD),
with increasing HR and decreasing heart rate variability
being associated with adverse outcomes [41].
Through these mechanisms, n-3 PUFAs seem to be able
to interfere with all the proarrhythmogenic mechanisms
responsible for the generation of ventricular arrhythmias.
In agreement with these proposed mechanisms, animal
experiments have demonstrated a beneficial effect of EPA and
DHA on the development of ischemia-induced ventricular
arrhythmias [42], whereas results from human studies are
more divergent. For ventricular arrhythmias generated by
other mechanisms, such as myocardial scaring and heart
failure, the same protective effect of n-3 PUFAs might not
be present, as suggested by the highly discrepant results of
n-3 PUFA supplementation in patients with an implantable
cardioverter defibrillator (ICD) [43–47].
3. The Omega-3 Index
The omega-3 index is defined as the content of EPA and DHA
in the cell membrane of red blood cells (RBCs), expressed as a
weight percentage of total FAs. The omega-3 index correlates
highly with the EPA + DHA content in serum, plasma, and
whole blood [48, 49], but as opposed to these findings, RBC
EPA + DHA is better correlated to long-term FA intake as
evaluated by a food frequency questionnaire (FFQ) and is
a more suitable biomarker for the nutritional status of an
individual [49]. The half-life of EPA + DHA in RBCs is
4–6 times longer than in serum [50], with concentrations
returning to baseline 16 weeks after supplementation [51].
In addition, the omega-3 index has been found to
be highly correlated with cardiac EPA + DHA levels and
responds to supplementation in a way very similar to that of
myocardial tissue [35, 36]. With RBCs readily available and
easy to analyze, this gives us the opportunity to apply the
omega-3 index as a surrogate for cardiac omega-3 status in
clinical practice.
4. N-3 PUFAs and Relation to
Cardiovascular Disease
The individual bioavailability of n-3 PUFAs along with
highly different designs, estimations of FA intake, or sup-
plementation dosages might be some of the reasons for the
inconsistent findings of studies evaluating the impact of n-3
PUFAs on CVD. A summary of the existing knowledge will
be given below.
4.1. Primary and Secondary Prevention Trials. The first
evidence of a possible health effect in humans with a
diet rich in n-3 PUFAs came from the pioneer studies
on Greenland Eskimos in the 1970s [1], reporting lower
coronary mortality in this population than in Danish control
subjects. Since then, a huge amount of the literature has been
published, further investigating the effects of these marine-
derived PUFAs on CVD. Two of the most cited studies are
the Diet and Reinfarction Trial (DART) investigating the
effect on recurrent cardiac events of dietary advice after a
recent MI [52] and the GISSI-Prevenzione trial in which
marine-derived n-3 PUFA supplementation was given for
the prevention of death, nonfatal MI, and stroke in patients
who had survived an MI during the preceding 3 months
[53]. In the DART study, 2 years of followup revealed a
29% reduction in total mortality (P < 0.05) among patients
advised to eat fatty fish, mainly due to a reduction in
deaths from coronary artery disease (CAD). Comparable to
this finding, supplementation with 1 g/day of n-3 PUFAs
(≈850 mg/day of EPA and DHA ethyl esters in a ratio of
1 : 2) for 3.5 years in the open label GISSI-Prevenzione study
reduced the composite endpoint of death, nonfatal MI, and
stroke by 15% (P = 0.023). In subgroup analyses, the
reduction in relative risk was even greater for cardiovascular
death and SCD which was reduced by 30% (P = 0.024) and
45% (P = 0.01), respectively.
It has been argued that the GISSI-Prevenzione trial was
not designed to evaluate SCD, and that it had insufficient
statistical power. The results of these subgroup analyses
should, therefore, be interpreted with caution. Furthermore,
there has clearly been an evolvement in the general treatment
of CAD from the time of performance of the GISSI trial
until today, and it has been argued that supplementation
with similar doses of n-3 PUFAs in addition to current
guideline-adjusted therapy might not have the same benefit.
The participants of the GISSI trial were included in the early
1990s, at a time when medical prescriptions and the use of
early coronary revascularization were quite different from
today’s management. To investigate this question, Rauch
et al. conducted the Omega trial, a randomized, placebo-
controlled, and double-blind trial evaluating the effects of 1-
year treatment with 1 g/day of n-3 PUFAs (380 mg DHA +
460 mg EPA) following an MI [54]. Treatment was initiated
3–14 days after MI in 3851 patients. As compared to the
GISSI trial in which 5% of the patients received coronary
revascularization at baseline, 93.8% of the participants of
the Omega trial underwent acute percutaneous coronary
intervention (PCI). The Omega trial revealed no effect on
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the rate of SCD (P = 0.84), total death (P = 0.18),
nonfatal reinfarction, stroke (P = 0.10), or revascularization
procedures in survivors (P = 0.34) after 1 year. The Omega
trial might, however, have been underpowered in an era of
more aggressive risk factor management.
No effect of n-3 PUFA supplementation could be demon-
strated on the risk of major cardiovascular events (fatal and
nonfatal CVD and cardiac intervention with PCI or coro-
nary artery bypass grafting (CABG)) in the Alpha Omega
Trial [55] in which 4837 patients receiving state-of-the-art
medical therapy after MI were randomized to one of four
margarines for 40 months; a margarine supplemented with
a combination of EPA and DHA, a margarine supplemented
with alpha-linolenic acid (ALA), a margarine supplemented
with EPA/DHA and ALA, or a placebo margarine. The
margarine compounds resulted in an uptake of 226 mg of
EPA combined with 150 mg of DHA, 1.9 g of ALA, or both,
respectively. As compared to placebo, neither EPA/DHA nor
ALA reduced the occurrence of the primary endpoint (HR
with EPA/DHA 1.01 (95% CI 0.87–1.17; P = 0.93); HR with
ALA 0.91 (95% CI 0.78–1.05, P = 0.20)). However, the dose
of marine n-3 PUFA used in this study was less than half of
the dose ingested in the GISSI trial [53].
As opposed to these studies, the GISSI-HF trial provided
evidence for a small, but beneficial, advantage of n-3 PUFA
supplementation on risk of total mortality (HR 0.91, 95.5%
CI 0.833–0.998, P = 0.041) and combined risk of total
mortality or admission to hospital for cardiovascular reasons
(HR 0.92, 99% CI 0.849–0.999, P = 0.009) in patients with
heart failure of any cause and irrespective of left ventricular
ejection fraction. These patients were given standard care
according to guidelines in the early 2000s [56]. In absolute
terms, 56 patients needed to be treated for a median duration
of 3.9 years to avoid one death or 44 to avoid one combined
event of death or admission to hospital for cardiovascular
reasons. In this randomized, double-blind, and placebo-
controlled trial, patients were given 1 g n-3 PUFAs daily
(n = 3494) or placebo (n = 3481) and followed for
a median of 3.9 years. Most interestingly, the same study
has demonstrated that n-3 PUFAs can provide a small
but significant improvement of left ventricular function in
patients with symptomatic heart failure [57]. Left ventricular
ejection fraction increased with n-3 PUFAs by 8.1%, 11.1%,
and 11.5% after 1, 2, and 3 years, respectively. In the placebo
group, the corresponding changes from baseline were 6.3%,
8.2%, and 9.9% (P = 0.005). This finding has recently been
verified in two smaller groups of patients with nonischemic
dilated cardiomyopathy receiving 1–4 g/day of n-3 PUFAs
versus placebo for 3–12 months [58, 59]. In one of these
studies, administrating supplements for only 3 months, a
dose-dependent increase in left ventricular function was
observed [58].
As opposed to the DART and GISSI trials, two recent
studies from Japan observed the reduction in risk of CAD
to be primarily related to nonfatal coronary events. The
Japan Public Health Centre-based (JPHC) study included
a total of 41 578 Japanese men and women aged 40–59
years initially free of CVD [60]. After 10 years of followup,
there was a 57% reduction in risk of nonfatal cardiac
events for the highest as compared to the lowest quintile
of fish intake [HR = 0.43 (0.23–0.81)], while no favourable
effect was observed on fatal events or SCD. In the Japan
EPA Lipid Intervention Study (JELIS), supplementation with
1800 mg EPA in combination with a statin was given to
18 645 hypercholesterolemic subjects (total cholesterol ≥
6.5 mmol/L) for a median time of 4.6 years [61]. Twenty
percent of these individuals presented with established CAD.
As compared to statin treatment alone, there was a 19%
relative reduction in the primary outcome measure including
SCD, fatal, and nonfatal MI and other nonfatal events
such as unstable angina pectoris, angioplasty, stenting, and
coronary artery bypass grafting (P = 0.011). Subgroup
analyses demonstrated, however, beneficial effects mainly
in the setting of secondary prevention with a significant
reduction in risk of unstable angina of 28% (P = 0.019).
The intake of n-3 PUFAs in these Japanese studies was
quite high, with participants of the upper quintile of fish
intake in the JPHC study having fish servings at least 8 times
per week and the population as a whole having a mean
intake of 900 mg n-3 PUFAs/day. In a review of prospective
cohort studies and randomized controlled trials, Mozaffarian
and Rimm [62] demonstrated evidence for a maximal risk
reduction of death from CAD with servings amounting to
about 250 mg n-3 PUFAs/day. We recently observed a similar
though nonsignificant threshold effect of dietary n-3 PUFAs
on risk of coronary events among patients undergoing coro-
nary angiography for suspected coronary artery disease [63].
Thus, for populations already consuming 250 mg/day of EPA
+ DHA, no further risk reduction for cardiac death seems
to be achieved. This threshold-related effect may explain the
lack of mortality benefit observed in the JPHC and JELIS
studies. Their background fish intake was associated with
very low coronary heart disease death rates (87% lower than
in comparable Western populations), and additional n-3
PUFA intake yielded little further reduction in the death rate,
as most of the population was already above the threshold for
maximum mortality benefit. In the JPHC study, only subjects
with a mean daily intake of 2.4 g n-3 PUFAs had any reduced
risk of nonfatal events, indicating that even greater dosages
might be needed to reduce the risk of nonlethal CAD events.
The choice of dose (1 g of n-3 fatty acids containing
465 mg EPA and 375 mg DHA per day) and the relatively high
background intake of n-3 PUFAs reported in the ORIGIN
trial (the Outcome Reduction with an Initial Glargine
Intervention) [64] might explain the lack of beneficial effects
of n-3 PUFAs on cardiovascular mortality and morbidity
in this study. This international, multicenter, randomized,
and open-label trial with a 2 × 2 factorial design evaluated
the protective effects of n-3 PUFAs in a daily dose of
1 g versus corn oil, and Insulin Glargine (Lantus) versus
standard care, on cardiovascular mortality and morbidity
during 6 years of followup in 12 536 high-risk subjects with
impaired fasting glucose, impaired glucose tolerance, or early
type 2 diabetes. The estimated median dietary intake of n-3
PUFAs of 210 mg/day might have muted the potential effects
of n-3 treatment, assuming that maximal risk reduction is
obtained by consuming 250 mg n-3 PUFAs/day, as suggested
by Mozaffarian and Rimm [62].
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Several other trials have confirmed an inverse association
between intake of n-3 PUFAs and risk of CAD [3, 65–70],
especially fatal cardiac events [65, 67–70]. This finding has
been evident both in the setting of primary [3, 65, 66, 68–
70] and secondary prevention [52, 53, 67]. Only a few
epidemiological studies and randomized controlled trials
have presented results indicative of a lack of effect [54, 55, 71–
74] or a direct harmful effect of a high intake of n-3 PUFAs
[75, 76]. The lack of effect on CAD from a relatively high
intake of n-3 PUFAs in Western coastal populations has
been suggested to be due to a concomitant high intake of
saturated FAs and monounsaturated FAs [77]. The Western
coastal populations differ not only from the Japanese with
respect to n-3 PUFA levels; they also ingest more of the
apparently unhealthy FAs with a possible attenuation of the
health effects of n-3 PUFAs. In this setting we cannot rule
out the harmful effects of environmental contaminants of
fish and increases of oxidative stress, as previously discussed.
The major clinical trial data for primary and secondary
prevention of CVD are summarized in Table 2(a).
4.2. Studies on Antiarrhythmic Effects. Time-course analyses
of the GISSI-Prevenzione study with a reduction in SCD
already after 4 months of supplementation [83] have given
rise to the hypothesis of a predominant antiarrhythmic effect
of n-3 PUFAs. This hypothesis is supported by a case control
study including 334 patients with primary cardiac arrest
performed by Siscovick et al. [84] who demonstrated that
an intake of 5.5 g of n-3 PUFAs per month (equivalent to
one fatty fish meal per week) as compared to no intake
was associated with a 50% reduction in the risk of cardiac
arrest (95% CI 0.4–0.8). All cases and controls were free
of prior clinical heart disease. In the same study, there
was an inverse relationship between blood measurements
of EPA + DHA and risk of cardiac arrest. The same has
been evident for SCD in the Physicians’ Health Study [85]
and for fatal ischemic heart disease in the Cardiovascular
Health Study [86]. In the latter study, patients over the age
of 65 had a 77% lower risk of assumed arrhythmic death
for each standard deviation increase in plasma phospholipid
DHA + EPA. None of these studies can, however, document
an antiarrhythmic mechanism of protection against SCD, as
the electrical activity of the myocardium at the moment of
cardiac arrest was not systematically registered.
The first evidence of an antiarrhythmic potential of n-
3 PUFAs came from experimental work in animal models
[87–90], and in a systematic review and meta-analysis of
the impact of n-3 PUFAs on selected arrhythmia outcomes
in these animal models, Matthan et al. [90] conclude that
there is a beneficial effect of EPA and DHA on ischemia-
induced ventricular fibrillation (VF) and ventricular fibril-
lation (VT) across all species. For ventricular arrhythmias
induced by reperfusion, the results were inconsistent, and
none of the animal models evaluated other arrhythmogenic
mechanisms, such as scar-related malignant arrhythmias.
In attempts to determine whether n-3 PUFAs could
have the same antiarrhythmic effects in humans, several
studies have been performed in ICD patients with a high
risk of recurrent ventricular arrhythmias. Schrepf et al.
[45] were able to abort the inducibility of VT in 5 out of
7 ICD patients undergoing electrophysiological testing by
intravenously infusing 3.8 g of n-3 PUFAs. The same finding
was recently published by Madsen et al. [81] testing eight
ICD patients undergoing a randomized, placebo-controlled,
crossover study with electrophysiological testing performed
both after infusion of 3.9 g of n-3 PUFAs and placebo. Of the
5 patients who were inducible after placebo, 2 were no longer
inducible after n-3 PUFAs infusion, and another 2 required
stronger stimulation to induce VT. Comparable to these
findings, Christensen et al. [46] have also demonstrated that
ICD patients with a low content of n-3 PUFAs in serum have
a higher incidence of ventricular arrhythmias as compared to
patients with high serum levels (P < 0.05).
Results have been less consistent in studies of orally
administered supplementation of n-3 PUFAs. Leaf et al.
[47] could only demonstrate a trend toward prolonged time
to the first ICD event (VF or VT) for patients receiving
4 g/day of fish oil supplements (total dose of EPA and DHA
of 2.6 g/day) as compared to olive oil supplements for 12
months, while Metcalf et al. [44] found that a daily dose of
3 g encapsulated fish oil for approximately 6 weeks resulted
in noninducible or less inducible VT in a group of patients
with ischemic cardiomyopathy. Brouwer and colleagues [78]
found no strong evidence for a protective effect of a daily
dose of 0.9 g n-3 PUFAs for 1 year as compared to that of
sunflower oil in 546 ICD patients. A similar dose (1 g/day of
n-3 PUFAs) did, however, result in a trend toward protection
in a substudy of the GISSI-HF trial when given to 566
patients for a median followup duration of 928 days [79].
There was a nonsignificant 20% reduction in appropriate
ICD managed VT/VF events in the n-3 PUFA group as
compared to placebo. Interestingly, this did not result in
any mortality benefit. There was actually a minimal excess
in total mortality observed in the group treated with n-3
PUFAs (26.6% versus 24.3%). This is in some contrast to
the results of the main study where the greatest proportion
of the absolute risk reduction of total mortality by n-3
PUFA supplementation was attributable to a reduction in
presumed arrhythmic deaths [56]. Moreover, in the study by
Raitt et al. [80], recurrent episodes of VT or VF during 2
years of followup occurred more frequently and with reduced
time to event in patients receiving 1.3 g/day of EPA/DHA as
compared to olive oil.
As previously mentioned, the protective effect of n-3
PUFAs might be strongest for ischemia-induced ventricular
arrhythmias. The implantation of an ICD is more often
performed in the setting of VF or VT without a concomitant
MI or any reversible cause or in the case of high risk of SCD,
such as excessive heart failure or demonstration of inducible
VF/VT at electrophysiological examination. Even though
ischemia might contribute to recurrent arrhythmic events,
these patients may also have other arrhythmic substrates
which to a lesser degree may be affected by n-3 PUFAs.
The mixture of both VF and VT as a primary endpoint in
most of the ICD studies also complicates the comparisons.
The study by Christensen et al. [46] demonstrating a
significantly lower frequency of ICD events for patients with
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the highest serum content of n-3 PUFAs reported only a
reduction in the presence of VF. Even though a reduction
in inducible VT has been achieved in both animals and
humans after infusion of n-3 PUFAs as well as after high-
dose supplementation [44], it is not known whether these
marine PUFAs in normal dietary or supplementary ingested
doses have the same potential to reduce the occurrence
of spontaneous VT as compared to VF. It is, however,
interesting to note that those studies reporting no beneficial
effect of oral supplementation seem to have the highest
proportion of patients with only VT prior to inclusion
[78, 80]. Furthermore, there is a high diversity between the
ICD studies in supplementation doses and the length of the
intervention, making an overall conclusion even harder to
achieve.
In agreement with a possible antiarrhythmic effect in the
setting of ischemia-induced ventricular arrhythmias, we have
recently presented evidence for a reduced risk of VF during
the acute ischemic phase of an MI with high levels of cellular
EPA and DHA [91]. After adjustment for other potential
predictors of risk of VF, our case-control study including 10
patients with VF during the initial 6 hours of symptom onset
suggested a 48% reduction in risk of this life-threatening
arrhythmia with a 1% increase of the omega-3 index. We
have later been able to reproduce the same finding in another
SCD population comprising 12 case patients with a first-time
MI [82]. The main strength of both of these studies is the
documentation of VF at the time of cardiac arrest, lending
support to the hypothesis of an antiarrhythmic effect of
n-3 PUFAs. Interestingly, results of the electrophysiological
studies performed both in animals [88] and humans [45,
81], demonstrating reduced inducibility or termination
of ventricular arrhythmias immediately after IV infusion
of n-3 PUFAs, also suggest that incorporation of marine
PUFAs into cell membranes might not be necessary for
their antiarrhythmic effect. The major clinical trial data on
antiarrhythmic effects are given in Table 2(b).
4.3. Meta-Analyses. A meta-analysis by Hooper et al. pub-
lished in Britical Medical Journal (BMJ) in 2006 was given
a lot of attention in media due to the conclusion that n-3
PUFAs given for at least 6 months had no clear effect on total
mortality or combined CVD events [92]. This analysis was
based on 41 cohort studies and 48 randomized intervention
trials including both patients with and without established
CVD but has later been criticized for several methodological
problems. A recently published meta-analysis by Filion et
al. [93] comprising 29 randomized controlled trials (RCTs)
including 35 144 high-risk CVD patients could neither
demonstrate a statistically significant decrease in total mor-
tality (RR 0.88, 95% CI 0.64–1.03) nor an effect on restenosis
prevention (RR 0.89, 95% CI 0.72–1.06) by n-3 PUFAs.
The results of these reviews differ, however, from several
other meta-analyses evaluating observational studies and
RCTs [94–99]. They all demonstrate a reduced risk of cardiac
death with increasing intake of marine PUFAs. The review
by He et al. [95] could actually demonstrate a 7% lower
risk of coronary heart disease mortality for each 20 g/day
increase in fish intake. The results are less consistent when
evaluating the effect of n-3 PUFAs on nonfatal CVD events.
Yzebe and Lievre [96], including 10 RCTs comprising 14
727 patients in their analysis, found no significant effects
on nonfatal MI, nonfatal stroke, or the presence of angina
pectoris. The same lack of influence by n-3 PUFAs on the
incidence of nonfatal MI was observed by Bucher et al.
[99]. This is opposed to the outcome from the review of
11 RCTs including 39 044 patients performed by Marik and
Varon [97] where dietary supplementation with n-3 PUFAs
significantly reduced the risk of nonfatal CVD events (OR
0.92, P = 0.02). The latter finding might, however, be due
to the fact that 48% of the patients included in that meta-
analysis belonged to the JELIS study [61]. Furthermore, the
heterogeneity of the effect of n-3 PUFA intake on CVD
outcome might be related to the impact of varying doses and
time of followup.
In a meta-analysis by Kwak et al. [100] involving
20 485 patients with a history of cardiovascular disease
from 14 randomized, double-blind, and placebo-controlled
studies, intervention with EPA and DHA showed insufficient
evidence of a secondary preventive effect of n-3 PUFA
supplements against overall cardiovascular events. JELIS [61]
and GISSI 4 [53] were excluded from this analyses, as these
were open studies.
The reduced risk of cardiac death associated with the
intake of n-3 PUFAs has largely been attributed to the
prevention of SCD. Two meta-analyses have specifically
evaluated this outcome. Both Marik and Varon [97] and
Chen et al. [98] found a reduced risk of SCD to be associated
with the intake of n-3 PUFAs. In the study by Chen et al.,
this effect was, however, limited to CVD patients without
guideline-adjusted therapy (RR 0.64, 95% CI 0.51–0.80).
There are only a couple of meta-analyses available
regarding the effect of n-3 PUFAs in ICD patients [43, 101],
both of which include the previously described studies by
Leaf et al. [47], Brouwer et al. [78], and Raitt et al. [80]. None
of these studies support a protective effect of n-3 PUFAs from
fish oil on cardiac arrhythmia in patients with an ICD.
However, the difficulties in interpreting meta-analyses
are clearly demonstrated by the recently published two
meta-analyses by Rizos et al. [102] and Delgado-Lista et al.
[103] evaluating the efficacy of omega-3 PUFAs on CVD,
including 12 of the same studies, but drawing opposite
conclusions. Both include randomized controlled trials in
primary and secondary prevention, but the endpoints differ.
Rizos et al. [102], including 20 studies, conclude that omega-
3 PUFA supplementation was not associated with a lower
risk of all-cause mortality, cardiac death, sudden death,
myocardial infarction, or stroke, based on relative and
absolute measures of association. On the contrary, Delgado-
Lista et al. [103], including 21 studies, conclude in favour
of omega-3 fatty acids, stating that marine omega-3 fatty
acids are effective in preventing cardiovascular events of
any kind (composite endpoint of stroke, coronary events,
myocardial infarction or angina pectoris, peripheral limb
disease events, or death from cardiovascular causes), cardiac
death, and coronary events, especially in persons with high
cardiovascular risk.
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4.4. Studies on Triglycerides. The triglyceride-lowering effect
of marine n-3 PUFAs is well recognized and has been
demonstrated to be linearly dose-dependent across a wide
range of consumption. As early as in 1990, Schmidt et
al. performed their dose-response studies on the effect of
marine n-3 PUFAs on triglyceride levels, showing that 6
weeks of supplementation with 1.3, 4, and 9 grams of n-
3 PUFAs daily to healthy normolipidemic men resulted in
a reduction in plasma triglycerides by 9%, 25%, and 33%,
respectively, in response to increasing doses of n-3 PUFAs
[33]
The minimal effective dose of marine n-3 PUFAs has
been demonstrated to be about 1 gram daily, also in
accordance with observations in the GISSI study, where 1 g
marine n-3 PUFAs for 6 months resulted in a small, but
significant, triglyceride reduction [53].
Even greater dose-dependent reductions in plasma levels
of triglycerides of 40%–50% have been observed among
individuals with hypertriglyceridemia. The American Heart
Association (AHA) [104] recommendations state that EPA-
DHA supplements may be useful in patients with severe
hypertriglyceridemia (>500 mg of triglycerides per deciliter
(5.6 mmol per liter)) in doses of 2 to 4 g of EPA-DHA per day
to lower triglyceride levels by 20% to 40% in people in whom
diet and lifestyle measures have not led to appropriate con-
centrations of triglycerides. This is also in agreement with the
US National Cholesterol Education Program (NCEP) [105].
However, a meta-analysis studying the triglyceride-lowering
effect of marine n-3 PUFAs in a daily dose of 4 grams
administered to subjects with moderate hypertriglyceridemia
(triglycerides 150–500 mg/dL) concludes that marine n-3
PUFAs are effective in reducing triglycerides by approxi-
mately 30% [106]. Additional lipid disturbances and CVD
risk factors should be considered before therapeutic deci-
sions are made. Although clinical studies have reported
considerable triglyceride-lowering effects by marine n-3
PUFA supplementation, no data for clinical endpoints are
available to lend support to this recommendation. Further
investigation is needed to explore this area.
5. The Omega-3 Index—A New Risk
Factor for CAD?
The omega-3 index has during the recent decade been
proposed as a new risk factor for CVD, especially for fatal
cardiac events [48, 107, 108]. This index is an independent
measurement of the amount of EPA and DHA available
in the body, highly reflecting the FA composition of the
myocardium [35–37]. In case-control studies the omega-
3 index has been demonstrated to be an independent risk
marker for SCD [84] and for the development of an ACS
[109, 110].
We could, however, not demonstrate any prognostic
utility of the omega-3 index in the setting of secondary
prevention in 460 ACS patients from the “Risk Markers in the
Acute Coronary Syndrome study” (RACS) [111] with respect
to future cardiac events or risk of death after adjustment
for traditional risk factors and established risk markers. We
have, however, in two different populations of first-time MI-
patients demonstrated low levels of the omega-3 index to
be independently associated with increased risk of cardiac
arrest/VF during the acute ischemic phase of an MI [82, 91].
The omega-3 index appears to fulfill many of the criteria
required for a risk marker/risk factor, especially for SCD
[48, 107, 108]. It has been estimated that the highest risk
of cardiac death is associated with an omega-3 index below
4%, with a level of 8% offering the greatest degree of
cardioprotection [48, 108]. These estimates correspond well
with the actual measurements in our cardiac arrest patients
but could not be confirmed as cut-points to classify patients
at low, intermediate, or high risk in our prognostic study.
Further studies are needed to elucidate the final role of the
omega-3 index in a clinical setting.
6. Conclusions and Further Perspectives
Despite a significant amount of research since the pioneering
work of Bang and Dyerberg in the 1970s attempting to
elucidate the possible health effects of n-3 PUFAs, there are
still several areas of uncertainty. The existing literature is,
however, mainly supportive of a cardioprotective effect of
marine fish oils, even though there is some disagreement as
to whether this effect is mediated through a reduced risk of
fatal or nonfatal cardiac disease. This might, however, be a
question of an optimum dose or whether there exists a dose-
response relation for n-3 PUFA supplementation. A final
conclusion is difficult to reach, as studies differ in design
and are performed in highly different patient populations
with different background intake of fish and reflect the
administration of a wide range of supplement doses of n-
3 PUFAs for varying periods of time. We definitely need
more high quality, large-scale, randomized, and controlled
clinical trials of long-term duration also reporting possible
harmful effects. Furthermore, studies on out-of-hospital
cardiac arrest will hopefully answer some more questions
related to the association between n-3 PUFAs and risk
of SCD. Moreover, to diminish difficulties in interpreting
meta-analyses, future meta-analyses should strive to include
trials with more homogenous designs and populations with
respect to cardiovascular risk profile, using similar doses of
marine n-3 PUFAs, with precisely defined endpoints.
We are still awaiting results of three large-scaled trials
which might contribute to a further understanding of the
appropriate role of n-3 PUFAs in the primary prevention
of cardiovascular events in both high- and low-risk partic-
ipants. In the large ASCEND (A Study of Cardiovascular
Events in Diabetes) trial, 15 480 diabetic patients (type I and
II) without CVD at the time of inclusion were randomized
with a 2 × 2 factorial design to receive low-dose aspirin
(100 mg), n-3 PUFA 1 g/day, both regimens or placebo in
a 2 × 2. Followup is scheduled to continue until 2017. No
publication is yet available. The Rischio and Prevenzione
study has between 2004 and 2007 randomized 12 513
participants without a previous MI to a daily dose of 1 g
of n-3 PUFAs or placebo (olive oil) for 5 years to evaluate
the influence of n-3 PUFAs on death or hospitalization
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Table 3: Official recommendations for the use of marine n-3 fatty acids in CVD prevention.
Primary prevention Secondary prevention
The American Heart
Association (AHA)1
Eat a variety of fish, preferably oily fish (salmon,
tuna, mackerel, herring, and trout), at least twice a
week. Consuming fish oil supplements should only
be considered by people with high levels of
triglycerides who consult with their physicians.
Consume about 1 gram per day of the fish oils EPA
and DHA (eicosapentaenoic and docosahexaenoic
acids), preferably from oily fish, although EPA +
DHA supplements could be considered in
consultation with their physicians.
People who have elevated triglycerides may need two
to four grams of EPA and DHA per day provided as
capsules under a physician’s care.
European Society of
Cardiology (ESC)
Eat fish twice a week, of which once oily fish2.
The recommended doses of total EPA and DHA to
lower triglycerides have varied between 2 and
4 g/day. Use of n-3 fatty acids (prescription
products) as an adjunct to the diet if triglycerides
exceed 5.6 mmol/L (496 mg/dL)3.
Eat fish twice a week, of which once oily fish2.
The recommended doses of total EPA and DHA to
lower triglycerides have varied between 2 and
4 g/day. Use of n-3 fatty acids (prescription
products) as an adjunct to the diet if triglycerides




Encourages increased consumption of omega-3 fatty
acids in the form of fish or in capsule form (1 g/d)
for risk reduction. For treatment of elevated
triglycerides, higher doses are usually necessary for
risk reduction4.
International Society for
the Study of Fatty Acids
and Lipids (ISSFAL)5
A minimum intake of eicosapentaenoic acid (EPA)








Recommends the equivalent of 450 mg marine
omega-3 daily and an increase in population oily fish
consumption to one portion a week.
Recommends the equivalent of 450 mg marine
omega-3 daily and an increase in population oily fish
consumption to one portion a week.
World Health
Organization (WHO)7
Regular fish consumption (1-2 servings per week) is
protective against coronary heart disease and
ischaemic stroke and is recommended. The serving
should provide an equivalent of 200–500 mg of
eicosapentaenoic and docosahexaenoic acid.
Regular fish consumption (1-2 servings per week) is
protective against coronary heart disease and
ischaemic stroke and is recommended. The serving
should provide an equivalent of 200–500 mg of
eicosapentaenoic and docosahexaenoic acid.
1http://www.heart.org/.
2European Guidelines on cardiovascular disease prevention in clincal practice (version 2012). The fifth joint task.
Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. EHJ 2012; 33: 1635-1701.
3ESC/EAS Guidelines for the management of dyslipidaemia. The Task Force for the management of dyslipidaemias of the European Society of Cardiology
(ESC) and the European Atherosclerosis Society (EAS). EHJ 2011; 32(14): 1769-1818.
4AHA/ACC Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 update endorsed by the
National Heart, Lung, and Blood Institute. JACC 2006; 47(10): 2130-9.
5 http://www.issfal.org/.
6Advice on Fish Consumption: Benefits and Risks was published in 2004 by the joint SACN/COT Subgroup (SACN 2004).
7World Health Organization (WHO) 2003: “Diet, Nutrition and the Prevention of Chronic Diseases.”
for cardiovascular events. Finally, the third large study,
the Vitamin D and Omega-3 Trial (VITAL), is currently
recruiting 20 000 participants in the US without a history
of CVD and cancer, for supplementation with Vitamin D
and/or 1 g n-3 PUFAs, to assess the preventive effects of n-
3 PUFAs on these conditions.
The official recommendations for the use of marine n-
3 fatty acids in CVD prevention by major official organi-
zations such as The American Heart Association (AHA),
the European Society of Cardiology (ESC), the International
Society for the Study of Fatty Acids and Lipids (ISSFAL),
and the World Health Organization (WHO) are given in
Table 3. However, based on the existing knowledge, the
general recommendation of fish or fish oil supplements
in patients at risk of, or with established CVD, has not
been substantiated, but high doses of n-3 PUFAs appear
to be safe in combination with current recommendations
regarding medical treatment of CAD patients, especially
when combined with aspirin and clopidogrel [112].
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